U.S. Markets closed

La Jolla Pharmaceutical Company (LJPC)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
30.42+1.16 (+3.96%)
At close: 4:00PM EDT
People also watch
NBIXINSMLGNDIMMUTGEN
  • Back over $30. Nice
  • Think we are screwed!! Let's hope Tang is not unloading little by little. Guess we will know soon when he has to report to SEC of his holdings.
  • Wrong again Chi. shorts lose.
  • Bye bye Bashers,,..shorts only could cover 119k shares last month

    Out of 5 MILLION Sweet times
  • 101% tute owned and 5 million short? Hawwww And phase 3 Already Topline
  • If you look at the last 2 days of trading, short interest and open interest in the options market, all signs point to LJCP moving north toward $30 or slightly over by the end of Friday. I don's see a major breakout, but short positions will definitely cover as the options market rolls their options into the next period.

    This will move the price northwards about 5-10%.
  • SQUEEZE HARDER WHEEEEE LONG TERM GAIN NOW OVER 6 figures

    Add ARNA and ya got millions
  • 35 fuzillon guIllion tutullion on this .... Yeah yaeh yeah. Been there done that.
    Wait for this to be delisted by end of August. Good luck everyone!
  • next news will be our buyout/merger/partnership

    put a 2 billon MC on LJ

    thats $135
  • Betting continues - 5.1 million shorted shares 5/15/2017 date. Actually increased so slightly from 4/30/2017 - 5.01 million shares.
  • "The ATHOS-3 trial is an important study because it provides intensive care clinicians with very strong data that angiotensin II [LJPC-501] is an effective and safe vasopressor drug when added to other vasopressor drugs in the management of shock," said Bellomo, the Australian intensive care doctor and investigator in the study.

    "The mortality data suggest the need for larger trials to test whether angiotensin II [LJPC-501] therapy increases survival in this very sick group of patients," he added.

    Lead ATHOS-3 study author Dr. Ashish Khanna of the Cleveland Clinic believes it's a mistake to brush off the significance of having another class of drug to raise blood pressure in critically ill shock patients.

    "What it means for the bedside clinician is we have now completed this jigsaw puzzle of three different pieces -- catecholamines, vasopressin and now angiotensin -- needed for a robust blood pressure response. With all three, we should be able to achieve a system where we can keep them balance so we can actually do good service to the human body. We supply patients with what is needed, keep their blood pressure normal, prevent organ injury and then fix the source of the problem," said Khanna.

    If LJPC-501 is approved and widely adopted by hospital emergency rooms and intensive care units to treat the most at-risk distributive shock patients, peak sales could reach $500 million annually, according to Cowen analyst Phil Nadeau. He has an outperform rating on La Jolla.
  • Below $5 crash!
    "The mortality data suggest the need for larger trials to test whether angiotensin II [LJPC-501] therapy increases survival in this very sick group of patients," he added.
    drug did not improve total organ function or reduce mortality, according to results from a phase III clinical trial presented Sunday.
  • 501 will be approved, and further prospective trials where it would be front line should follow to seek safety and further show its long term survival outcomes in the theses critically ill patients. Mortality with our current options is higher than 50%. This new option needs and should be explored
    Further. The FDA has enough to approve it . Once investing chatter and shorting is thin , smart money is on 501
  • 5 million + shares shorted as of 4/30/2017. It appears these shorts are betting that the Phase 3 full report is not as validation of great results as per previous press release. If they do not have some sort of inside info and the NEJM article is really positive, these shorts will get hammered. It is almost 40% of the float. If they continue to short and keep their short position and if the drug does get FDA approved, assume by the end of this year, they could really, really get hammered. $100 share price is only $2 billion market cap and there should not be anymore dilution prior to all this (at least for another full calender year). If it is FDA approved, I would think Shaniqua may be right about a buy out possbility.
  • 5+ million shares shorted as of 4/30. I assume not much of that was covered in last 20 days since those shorted were counting on big dump after full disclosure report. We will have to wait another week to see where the short position is. Can these shorts wait out until FDA approval decision (speculating for rejection)? No one knows for sure but I would not feel too comfortable holding any short positions right now (LJPC 401 phase 2 status to be out in next few months and LJPC 501 FDA approval by end of this year).
  • 70% vs. 28% ON primary end point! Shorts cant stand the fact they lose! This drug increases BP not reverse organ failure. Even 1% improvement in mortality is a win! Ask the patient that survived! They used the product in the worse patients. It still performed! If this was used earlier in organ dysfunction the Mortality data would have been a lot better. Once a patient develops organ failure...Kidney, lung and liver either one or all its hard to bring a patient back. But if you shorts want to take it down to 5$ that is fine with me. I will load up. Remember where this drug is being metabolized and yet it still performed well. Yes, once the drug is commercial then you can run more studies. Organ failure is different than organ dysfunction!
  • just, christy, and silver are one person -- IDs have just posting here but they were posting at couple of other sites.
  • 5.15 million shares shorted - 5/15/017. This number increased or decreased since the NEJM article?
  • When looking at just cardiovascular organ function, a subset of the total SOFA score, LJPC-501 did show a statistically significant improvement compared to placebo at 48 hours. La Jolla believes this result is clinically significant outcome because it shows LJPC-501 can help doctors wean distributive shock patients off higher, more toxic doses of catecholamines.

    LJPC-501 demonstrated a 22% reduction in the risk of death after seven days compared to placebo, but the difference was not statistically significant. After seven days, 29% of the LJPC-501 patients died compared to 35% of placebo patients.

    "The ATHOS-3 trial is an important study because it provides intensive care clinicians with very strong data that angiotensin II [LJPC-501] is an effective and safe vasopressor drug when added to other vasopressor drugs in the management of shock," said Bellomo, the Australian intensive care doctor and investigator in the study.

    "The mortality data suggest the need for larger trials to test whether angiotensin II [LJPC-501] therapy increases survival in this very sick group of patients," he added.

    If LJPC-501 is approved and widely adopted by hospital emergency rooms and intensive care units to treat the most at-risk distributive shock patients, peak sales could reach $500 million annually, according to Cowen analyst Phil Nadeau. He has an outperform rating on La Jolla.

    "Our consultants says there is a desperate need for new options in the CRH patient population, and that any agent that demonstrates an ability to increase blood pressure will be adopted," Nadeau wrote in a recent research note. CRH refers to distributive shock patients who don't respond to first-line treatment with catecholamines.
  • 501 should be the front line drug since it works better than those used prior. These results were known already